Vertex Energy filed for Chapter 11 bankruptcy, supported by term loan lenders and seeking a comprehensive restructuring.

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group ...

Fuel refiner Vertex Energy Files for Bankruptcy protection, citing $422.5 million in debt. The Houston-based company made the ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...

Discover Vertex Pharmaceuticals' groundbreaking patent for variant PD-1 polypeptides, enhancing immunomodulatory proteins for innovative cancer and immune therapies.

PartnershipLonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) 24.09.2024 / 14:00 CET/CEST Lonza to manufacture CASGEVY®, the world’s first ...

Bluebird bio will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on Tuesday, in a second major restructuring in two years as the company focuses on launching its ...